Do projects have a speed limit?

Speakers for this event

• Cav Elithorn

  Cav Elithorn

  Director Rail Infrastructure Central, Dept of Transport

  Cav joined the DfT 8 years ago working on the reclassification of Network Rail and then Rail Strategy. He moved across to High Speed 2 working on delivery of wider benefits (e.g. regeneration around stations) including delivering the Master Development Partner for Euston. In 2018 he moved into infrastructure delivery as SRO (Senior Responsible Owner) for East West Rail and Director for Crossrail 2 subsequently expanding into wider Rail Infrastructure North with a changing portfolio of rail enhancements projects currently including Midland Mainline Electrification. He is the DfT Lead for Rail Project SPEED.
  Cav started his career in Strategy Consulting, then moved to marketing in financial services before joining the Office of Fair Trading where he led major investigations, was Transformation Director and introduced the OFT’s Project Delivery Framework.

  Director Rail Infrastructure Central, Dept of Transport

• Christine Schwaighofer

  Christine Schwaighofer

  Director, Global Project Management, AstraZeneca

  Christine is a Ph.D-trained biologist with 20 years of Oncology R&D experience in academic and pharmaceutical settings. She started her career in Germany, and has also worked in the US and the UK. In 2018 she joined AstraZeneca as a global project manager. She is currently managing two high priority, highly accelerated early clinical projects.

  Director, Global Project Management, AstraZeneca

• Dave Walker

  Dave Walker

  Industry Consultant

  Expert in drug development of both medicinal products and medical devices plus experience in ATMPs. Experience spanning over 35 years with recent experience in Clinical Development at senior management level and prior work in both discovery and preclinical arena.
  Personal goals has always been to construct or support high performing teams and strive to get the best out of everyone by maximising both their individual potential and by encouraging group contributions from all.

  EXPERIENCE
  Currently an independent pharmaceutical consultant since January 2022, previous experience includes leading the Clinical Development function at Norgine in Phase 1-IV clinical studies and supporting due diligence assessments for Business Development and Norgine Ventures. From 2008-12, was Company Director with Pgxis-Cytopathfinder holding multiple responsibilities in the acquisition and development of products towards added value for future partnering. Previously over 20 years at GlaxoSmithKline with Project Leader & Programme Management roles in multiple therapeutic areas.

  Industry Consultant

• Denise Moody

  Denise Moody

  COO, Kuano

  Denise is Chair of PIPMG

  COO, Kuano

• Jeremy Cooper

  Jeremy Cooper

  Founder, performance coach at Balanced Life

  With over 20 years’ working in IT and Life Sciences, Jeremy has a wealth of experience covering operations, architecture, projects, and leadership. During various roles Jeremy has had exposure to supporting companies through hyper growth, mergers, and acquisitions, building out high performing teams and transforming how services are delivered.
  However, it came at a cost.

  Due to his drive and work pressure (mostly self inflicted), he ended up burnt out and struggling to leave the house due to anxiety. Jeremy was a shell of a person that was just transacting through all aspects of life.

  During his recovery, Jeremy discovered how much our habits shape our work and lives, and strategic changes can transform us. Implementing these habits and showed them to others transformed his life and career, and led him to form Balanced Life with a mission to help individuals and organisations find High-Performance and Balance.

  Founder, performance coach at Balanced Life

• Joe Luis Diaz

  Joe Luis Diaz

  Executive Director, Global Project Management, Infection Franchise, AstraZeneca

  Jose Luis joined AstraZeneca in November 2014 as part of the AZ acquisition of the Almirall respiratory portfolio. Since joining AZ he has been Global Project Manager for the aclidinium franchise, PT027, anifrolumab and nirsevimab, respectively. Before leading the Vaccines and Immune Therapies (V&I) Global Portfolio and Project Management, Jose Luis has been Senior Director of Late R&I Project Management and member of the Biopharma PM Leadership Team, chair of the Late R&I Resource Council and Site Head for AZ Barcelona.

  Jose Luis received a BSc in microbiology from University College London and a PhD in Autoimmunity from the University of Southampton (UK). He has over 30 years’ experience in R&D, including 2 years in Glaxo and 8 years in USA Biotech companies before joining Almirall (Spain’s largest pharmaceutical company at the time) as Head of External Research.
  Outside of AZ his passions include his 3 daughters, wine, military history and rugby (not necessarily in that order).

  Executive Director, Global Project Management, Infection Franchise, AstraZeneca

• Joe Stalder

  Joe Stalder

  Exec. Director, Project Management at Mirati Therapeutics, Head of PIPMG USA Chapter

  Joe is leading a PM networking group on the west coast of the US and has made a proposal for this to become part of PIPMG. To expand across the US, one of Joe’s contacts is being asked to be the East Coast focus in addition. We are currently discussing with Joe and he will introduce this proposal at the meeting.

  Exec. Director, Project Management at Mirati Therapeutics, Head of PIPMG USA Chapter

• Phil Mallinder

  Phil Mallinder

  Executive Director Head of Early Oncology Project Management, AstraZeneca

  Phil started his career at AZ R&D Charnwood in Loughborough, working there for 17 years, initially as a discovery lab scientist, then managing a team of molecular biologists and ultimately becoming a project leader for both large molecule and small molecule projects generating several candidate drugs. Phil spent 2 years at PRECOS a pre-clinical oncology CRO before moving to Novartis as an early development Global Project Manager. Phil returned to AZ/Medimmune in 2014 and has spent the past 8 years as a project manager on a range of early oncology drug development projects. He was appointed as a team leader within Early Oncology Project Management when Global Portfolio and Project Management was formed within AstraZeneca in 2019 and has managed a team of up to 10 early oncology Global Project Managers advancing projects in the AZ early pipeline. Recently Phil has been appointed Head of Early Oncology Project Management and has oversight over all the ~30 Global Project Managers who manage ~50 early oncology projects from pre-candidate Drug investment decision to Phase 3 transition.

  Executive Director Head of Early Oncology Project Management, AstraZeneca

• Richard Scott

  Richard Scott

  Director, Global Project Management, AstraZeneca

  Richard has over 25 years’ experience of Drug Discovery & Development in Project and Business Partnering roles. Originally a Biochemist & Computational Chemist by training, he has worked in Cambridgeshire for Start-up Biotechs (Peptide Therapeutics & DeNovo Pharmaceuticals) and Big Pharma (Amgen & GSK) before joining AZ in 2017. As part of the GPPM Late Oncology Team as Director of Global Project Management, Richard has managed AZ’s flagship Lung Cancer drug Tagrisso, overseeing R&D budgets of $1Bn. The most recent ADAURA clinical study read out 2 years ahead of planned results, had an accelerated submission & launch and was presented at the European Society for Medical Oncology in September for disease-free survival results. Richard now supports the Savolitinib program that combats Tagrisso resistance.

  Director, Global Project Management, AstraZeneca

• Sandra Hirschberg

  Sandra Hirschberg

  Programme Director, Bicycle Therapeutics

  Sandra started her career as an immunologist, and during the past 20 years has had various roles in program management and leadership within big pharma, CRO and biotech companies. During the past 9 years Sandra has focussed on oncology and is currently a Program Leader at Bicycle Therapeutics.

  Programme Director, Bicycle Therapeutics

• Shauna Still

  Shauna Still

  Sr. Director Project Management, Infectious Diseases,   PPD, part of Thermo Fisher Scientific

  Shauna is a Senior Director with 22 years in the CRO industry, almost 17 with PPD, part of Thermo Fisher Scientific. Her tenure includes experience as a CRA, Clinical Management, Project Management, and leading and overseeing all phases of clinical development. She is located on the east coast of the USA, in Holly Springs, NC. Her experience has offered her opportunities in Master Study Trial Design, large scale organization restructures, and departmental leadership in both Site Start-up and Infectious and Respiratory Disease Units. She is led to work each day with a smile, driven by passion in 3 key areas: improved patient outcomes, talent development and the never-ending search process efficiency. When not working, she is fulfilled by her family, great food, a nice glass of wine and her kayak

  Sr. Director Project Management, Infectious Diseases,   PPD, part of Thermo Fisher Scientific

• Sheena Behn

  Sheena Behn

  VP V&I Supply Chain, VP TA Oncology, Global Supply Chain and Strategy, AstraZeneca

  Sheena Behn is an established global leader in the Pharmaceutical Industry with significant supply chain, manufacturing and development experience and expertise. She has worked at AstraZeneca for 25 years.

  Sheena is currently VP Vaccine and Immune Therapies Supply Chain and VP for Oncology Supply, based in Cambridge, UK.

  She was previously based in Gothenburg as VP R&D Supply Chain (2012-2014) running the global group for Clinical Supply at AZ; and before that VP for Wuxi Manufacturing site for 3 years, based in China (2010-2012).

  Sheena is a Pharmacist who started her career working in London hospitals, before working in pharmaceutical development with GSK and then AZ before joining Operations in 2007.

  VP V&I Supply Chain, VP TA Oncology, Global Supply Chain and Strategy, AstraZeneca